SCHEMBL6324049

SCHEMBL6324049

CCC(=O)Oc1ccco1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.46
MMP9 P14780 1/20 0.46
MMP12 P39900 1/20 0.46
KMT2A Q03164 6/20 0.43
ELANE P08246 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
ESR1 P03372 2/20 0.42
HIF1A Q16665 2/20 0.42
RECQL P46063 1/20 0.42
POLB P06746 3/20 0.41
MEN1 O00255 2/20 0.41
KDM4E B2RXH2 2/20 0.41
USP2 O75604 2/20 0.41
ALDH1A1 P00352 3/20 0.41
ACHE P22303 2/20 0.40
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TP53 P04637 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27680685 0.98 MMP1 (0.45) MMP1MMP9MMP12KMT2AELANE
SCHEMBL28576324 0.85 MMP1 (0.44) MMP1MMP9MMP12KMT2ASMN1; SMN2
SCHEMBL28942302 0.84 MMP1 (0.49) MMP1MMP9MMP12KMT2ASMN1; SMN2
SCHEMBL14989478 0.82 MEN1 (0.49) MMP1MMP9MMP12KMT2ASMN1; SMN2
SCHEMBL28776602 0.81 MMP1 (0.44) MMP1MMP9MMP12KMT2ASMN1; SMN2
SCHEMBL8665987 0.81 MMP1 (0.46) MMP1MMP9MMP12KMT2ARECQL
SCHEMBL31663477 0.80 POLM (0.46) KMT2ASMN1; SMN2RECQLMEN1KDM4E
SCHEMBL19973305 0.80 POLM (0.46) KMT2ASMN1; SMN2RECQLMEN1KDM4E
SCHEMBL28942304 0.79 MMP1 (0.45) MMP1MMP9MMP12KMT2ASMN1; SMN2
SCHEMBL28198283 0.79 MMP1 (0.42) MMP1MMP9MMP12KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111655372-B Catalysts containing furans and their use in hydrotreating and/or hydrocracking processes IFP 新能源公司 2023-07-25 CN claimed
CN-110092778-A A method of using cheap metal copper for vilazodone intermediate and vilazodone drug 浙江工业大学 2019-08-06 CN claimed
CN-109790407-A Printing ink composition and its preparation method and application 广州华睿光电材料有限公司 2019-05-21 CN claimed
CN-109790406-A Composition and its preparation method and application for printed electronic device 广州华睿光电材料有限公司 2019-05-21 CN claimed
CN-108239137-A Medical -16 α of hormone intermediate 11- ketone, the synthetic method of 17 α-epoxy progesterone 成都千叶龙华石油工程技术咨询有限公司 2018-07-03 CN claimed
CN-108137971-A Composition for printing electronics and use thereof in electronic devices 广州华睿光电材料有限公司 2018-06-08 CN claimed
CN-102627563-A Phthalic acid compound, its preparation method and application UNIV SICHUAN 2012-08-08 CN claimed
CN-101798316-B Triazolothiadiazole compounds and preparation method and application thereof NANKAI UNIVERSITY (CN) 2011-11-30 CN claimed
CN-101798316-A Triazolothiadiazole compounds and preparation method and application thereof UNIV NANKAI 2010-08-11 CN claimed
CN-119000986-B Method for judging processing degree of cape jasmine charcoal based on headspace-GC-IMS (gas chromatography-mass spectrometry) differential volatile components 中国中医科学院中药研究所 2025-06-10 CN disclosed
CN-119655345-A Coffee replica made from a single component 航行食品股份有限公司 2025-03-21 CN disclosed
CN-118742210-A Chocolate replicas made from multiple individual components 航行食品股份有限公司 2024-10-01 CN disclosed
CN-111655372-B Catalysts containing furans and their use in hydrotreating and/or hydrocracking processes IFP 新能源公司 2023-07-25 CN disclosed
US-11053279-B2 Methods for the site-selective coupling of a first agent to a second agent UNIVERSITEIT GENT (BE) 2021-07-06 US disclosed
CN-1046507-C Heterocyclic compounds for the treatment of central nervous system and cardiovascular diseases UPJOHN CO (US) 1999-11-17 CN disclosed
CN-1144091-A Compounds having retinoid-like activity ALLERGAN INC (US) 1997-03-05 CN disclosed
CN-1139431-A Heterocyclic compounds for the treatment of central nervous system and cardiovascular diseases PHARMACIA & UPJOHN CO LLC (US) 1997-01-01 CN disclosed
EP-0696306-A1 THERMOSETTING COATING COMPOSITIONS EASTMAN CHEMICAL COMPANY (US) 1996-02-14 EP disclosed
WO-1994025535-A1 THERMOSETTING COATING COMPOSITIONS EASTMAN CHEMICAL COMPANY (US) 1994-11-10 WO disclosed
US-5324788-A A copolymer of a 4-acyloxystyrene and an acrylate modified by an alcohol to effect an ester interchange, an aminoplast crosslinking agent and solvent; enamel coatings; acid and solvent resistance; hardness; gloss; autos EASTMAN KODAK COMPANY (US) 1994-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11053279-B2 Methods for the site-selective coupling of a first agent to a second agent PAICS, HNMT, DPYD MMP1 3787/4885MMP9 4805/4885MMP12 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.